To adapt to the hypo-vascular nature of pancreatic cancer, which is usually characterized by oxygen and nutrient deficiency, oncogenic KRAS promotes glucose transporter (GLUT1) and hexokinase gene transcription to enhance glucose transport and utilization [8]. The gene discussed is SLC2A1; the disease is familial pancreatic carcinoma.